

Curriculum Vitae

Date: March 8, 2020

First Name: Ali (Aliakbar)

Middle Initial: A

Sure Name: Asadi-Pooya

Biography: Born in Shiraz, Iran; 1973

Citizenship: USA-Iran

Affiliation: 1. Professor of Epileptology, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.

2. Adjunct Research Associate Professor, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.

Phone: +1-417-437-3053

E-mail: aliasadipooya@yahoo.com

H Index 20

Education

2014-2016 Postdoctoral Research Fellowship in Invasive Intracranial EEG Monitoring and Brain Stimulation, Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

2006-2008 Fellowship in Epilepsy and Clinical Neurophysiology, Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

1998-2001 Pediatrics Residency, Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran.

- 1997-1998** Internship, Shiraz University of Medical Sciences, Shiraz, Iran.
- 1991-1997** Medical Student, Shiraz University of Medical Sciences, Shiraz, Iran.

Administrative appointments (Director and Committee appointments)

- 2020-present** Director, Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- 2020** Co-Chair of the 13th Qatar Epilepsy Symposium, Doha, Qatar.
- 2019-present** Founding member, Functional Neurological Disorder Society (FNDS)
- 2019** Vice Principal of the 2nd Qatar International Epilepsy School.
- 2017-2021** Psychogenic Non-Epileptic Seizures Task Force Committee, International League Against Epilepsy (ILAE).
- 2018** Vice Principal of the 1st Qatar International Epilepsy School.
- 2008-present** Director, Epilepsy Care Unit, Namazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
- 2008-present** Director, Epilepsy Surgery Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
- 2008-2014** Director, EEG Laboratories, Shiraz University of Medical Sciences, Shiraz, Iran.
- 2013-2017** Psychogenic Non-Epileptic Seizures Task Force Committee, International League Against Epilepsy (ILAE).

Faculty employments

- 2019-present** Professor of Epileptology, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.

- 2016-present** Adjunct Research Associate Professor, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
- 2010-2019** Associate Professor of Epileptology, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
- 2008-2016** Adjunct Research Assistant Professor, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
- 2008-2010** Assistant Professor of Epileptology, Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.

Licensure and Certifications

- 2008** Fellowship, Epilepsy and Clinical Neurophysiology (Thomas Jefferson University, USA; approved by Ministry of Health & Medical Education, Iran)
- 2001** Specialty, Pediatrics (Iran)
- 1998** M.D. (General Physician # 73212), Iran

Honors and Awards

- 2020** National Distinguished Researcher Grant, NIMAD (National Institute for Medical Research Development), Iran (987669).
- 2019** National Distinguished Researcher Grant, NIMAD (National Institute for Medical Research Development), Iran (982487).
- 2018** National Distinguished Researcher Grant, NIMAD (National Institute for Medical Research Development), Iran (971003).
- 2015** ILAE Leadership Program award, Istanbul, Turkey.

- 2013** Excellence in Epilepsy Treatment, distinguished by the President of Shiraz University of Medical Sciences, Shiraz, Iran.
- 2010** The distinguished attending of the year at Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
- 2005** Young Investigator Award, The 26th International Epilepsy Congress, Paris.
- 2005** The 3rd Place in the 11th Razi Research Festival on Medical Sciences in Iran.
- 2005** The distinguished researcher of the year at Shiraz University of Medical Sciences selected by Vice-Chancellor for research of Shiraz University of Medical Sciences.
- 2005** The distinguished attending of the year at Shiraz Medical School, selected by Shiraz medical students.
- 2004** Active researcher of the year at Shiraz Medical School selected by Vice-Chancellor for research of Shiraz University of Medical Sciences.
- 2004** The distinguished attending of the year at Shiraz Medical School, selected by Shiraz medical students.
- 2003** The distinguished attending of the year at Shiraz Medical School, selected by Shiraz medical students.
- 2001** First Rank in the Board Examination of Pediatrics in Iran (135. 33/150).
- 1999** The Best researcher of medical students in Iran selected by Student Research Committee.
- 1998** First Rank in Shiraz Medical School in comprehensive examination of clinical sciences and average grade of clinical courses.
- 1997** The Best Student of Iran selected by Ministry of Health & Medical Education.
- 1993** Top Student of Shiraz Medical School in comprehensive examination of basic sciences.

Professional Activities and Memberships

2019-present Functional Neurological Disorder Society

2011-present American Epilepsy Society

2004-present Iran Epilepsy Association

Lectures by invitation

1. **Idiopathic Generalized Epilepsies.** The 13th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2020.
2. **Complementary and alternative medicine for epilepsy in the Middle East and North Africa (MENA) region.** The 13th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2020.
3. **PNES.** The 2nd Qatar International Epilepsy School, Hamad Medical City, Doha, Qatar, 2019.
4. **Dramas in Epilepsy.** The 2nd Qatar International Epilepsy School, Hamad Medical City, Doha, Qatar, 2019.
5. **Idiopathic Generalized Epilepsies.** The 2nd Qatar International Epilepsy School, Hamad Medical City, Doha, Qatar, 2019.
6. **Spike Voltage Topography.** The 12th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2019.
7. **Updates in Psychogenic Non-Epileptic Seizures.** The 12th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2019.
8. **Anti-epileptic devices.** 15th Iran International Epilepsy Congress, Tehran, Iran, 2019.
9. **Invasive Intracranial EEG Monitoring.** 15th Iran International Epilepsy Congress, Tehran, Iran, 2019.
10. **Treatment of Epilepsies.** Mashhad Epilepsy Symposium, Mashhad, Iran, 2018.

11. **Role of EEG in Children with Developmental Disability.** Pediatric Epilepsy School, Tehran, Iran, 2018.
12. **Role of EEG in Syndromic Diagnosis of Epilepsies.** The 25th Congress of Neurology and Clinical Neurophysiology of Iran, Tehran, Iran, 2018.
13. **Mortality in Epilepsy and after Epilepsy Surgery.** The 11th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2018.
14. **Idiopathic Generalized Epilepsies.** The 11th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2018.
15. **Uncommon Semiological Features of Epilepsies.** The 14th Iran Epilepsy Congress, Isfahan, Iran, 2018.
16. **Epileptic Encephalopathies.** Ahvaz Epilepsy Symposium, Ahvaz, Iran, 2018.
17. **EEG and Clinical features of PNES.** Qatar EEG and Epilepsy workshop, Doha, Qatar, 2017.
18. **Intracranial EEG and HFOs.** Qatar EEG and Epilepsy workshop, Doha, Qatar, 2017.
19. **How to Report Various EEG Findings.** Qatar EEG and Epilepsy workshop, Doha, Qatar, 2017.
20. **Novel Treatments for Epilepsy.** Mashhad Epilepsy Symposium, Mashhad, Iran 2017.
21. **Psychogenic Non-Epileptic Seizures Semiology.** Turkish Annual Semiology of Epilepsy Meeting, Istanbul, Turkey, 2017.
22. **Semiology in Epilepsies: Ictal Laughter, Ictal Crying, Ictal Pain.** Turkish Annual Semiology of Epilepsy Meeting, Istanbul, Turkey, 2017.
23. **Psychogenic Non-Epileptic Seizures: Recent Advances.** Grand Round, Hamad Medical City, Doha, Qatar, 2017.

24. **Ictal Laughter, Ictal Crying, Ictal Pain: Etiology and Semiological value.** 10th Qatar Epilepsy Symposium, Hamad Medical City, Doha, Qatar, 2017.
25. **Psychogenic Non-Epileptic Seizures: Services and Research in Iran.** The 70th Annual Meeting of the American Epilepsy Society, Houston, USA, 2016.
26. **Treatment of Non-Convulsive Status Epilepticus.** The 21st Congress of Neurology and Clinical Neurophysiology of Iran, Tehran, Iran, 2014.
27. **Psychogenic Non-Epileptic Seizures.** The 1st International Congress of Challenges in Clinical Neurology, Kerman, Iran, 2014.
28. **Establishing Epilepsy Care Services in Iran.** World Congress of Neurology, Vienna, Austria, 2013.
29. **Treatment of Focal Epilepsies.** The 10th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2013.
30. **Lateralizing and Localizing Semiologic Findings in Focal Epilepsies.** The 10th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2013.
31. **Antiepileptic Drugs in Hematology-Oncology Patients.** The 20th Congress of Neurology and Clinical Neurophysiology of Iran, Tehran, Iran, 2013.
32. **Epilepsy and Women.** Annual course in Obstetrics and Gynecology, Shiraz, Iran, 2012.
33. **EEG Techniques.** The 9th International Epilepsy Congress, Tehran, Iran, 2012.
34. **Treatment of Epilepsy.** The 19th Congress of Neurology and Clinical Neurophysiology of Iran, Tehran, Iran, 2012.
35. **Genetics and Pathogenesis of Epilepsy.** The 8th International Epilepsy Congress, Tehran, Iran, 2011.
36. **Status Epilepticus.** The 18th Congress of Neurology and Clinical Neurophysiology of Iran, Tehran, Iran, 2011.

37. **Antiepileptic Drug Interactions.** The 7th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2010.
38. **Practical Uses of Electroencephalography.** Fars Psychiatry Association Annual Updates, Shiraz, Iran, 2010.
39. **Treatment of Epilepsies.** Department of Neurosurgery Annual Updates, Shiraz University of Medical Sciences, Shiraz, Iran, 2009.
40. **Epilepsies in Children.** Hejazi Hospital Annual Updates, Shiraz, Iran, 2009.
41. **Epilepsy Surgery.** Epilepsy Updates, Department of Neurology Annual Congress, Shiraz University of Medical Sciences, Shiraz, Iran, 2008.
42. **Role of Wada Test in Epilepsy Surgery.** The 5th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2008.
43. **Corpus Callosotomy.** The 5th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2008.
44. **Treatment of Idiopathic Generalized Epilepsies.** Jefferson Medical College of Thomas Jefferson University, The 35th Annual Course in Electrodiagnostic Medicine and Clinical Neurophysiology, Philadelphia, PA, USA, 2008.

Publications

A. Peer-Reviewed Publications:

1. **Asadi-Pooya AA**, Bartolini L. Prevention and treatment of temporal lobe epilepsy: lessons from hepatitis B story! Int J Neurosci. 2020 Feb 27:1-5. doi: 10.1080/00207454.2020.1730370. [Epub ahead of print]
2. Pick S, Anderson DG, **Asadi-Pooya AA**, et al. Outcome measurement in functional neurological disorder: a systematic review and recommendations. J Neurol Neurosurg

Psychiatry. 2020 Feb 28. pii: jnnp-2019-322180. doi: 10.1136/jnnp-2019-322180.

[Epub ahead of print] Review.

3. **Asadi-Pooya AA**, Homayoun M. Medical comorbidities in patients with psychogenic non-epileptic seizures (functional seizures). *Neurol Sci*. 2020 Mar 4. doi: 10.1007/s10072-020-04315-7. [Epub ahead of print]
4. **Asadi-Pooya AA**, Brigo F, Mildon B, et al. Terminology for psychogenic nonepileptic seizures: Making the case for "functional seizures". *Epilepsy Behav* 2020; 104(Pt A): 106895.
5. Sawchuk T, **Asadi-Pooya AA**, Myers L, et al. Clinical characteristics of psychogenic nonepileptic seizures across the lifespan: An international retrospective study. *Epilepsy Behav* 2020; 102: 106705.
6. **Asadi-Pooya AA**, Homayoun M. Tonic-clonic seizures in idiopathic generalized epilepsies: prevalence, risk factors, and outcome. *Acta Neurol Scand*. 2020 Feb 6. doi: 10.1111/ane.13227. [Epub ahead of print].
7. **Asadi-Pooya AA**. International multicenter studies on psychogenic nonepileptic seizures: A systematic review. *Psychiatry Res* 2020; 285: 112812.
8. **Asadi-Pooya AA**, Dastgheib SA, Nazeri M. Disability benefits in patients with psychogenic nonepileptic seizures: a survey of physicians' opinions. *Epilepsy Behav* 2020; 103(Pt A): 106877.
9. Nazeri M, Dastgheib SA, **Asadi-Pooya AA**. Job consultation in patients with psychogenic nonepileptic seizures: Systematic review and survey of physicians' opinion. *Epilepsy Behav* 2020; 103(Pt A): 106863.
10. Kissani N, Lengané YTM, Patterson V, et al. Telemedicine in epilepsy: How can we improve care, teaching, and awareness? *Epilepsy Behav* 2020; 103(Pt A): 106854.

11. Nicholson TR, Carson A, Edwards MJ, et al. Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. *J Neuropsychiatry Clin Neurosci* 2020; 32: 33-42.
12. **Asadi-Pooya AA**, Homayoun M. Psychogenic nonepileptic seizures: The sex ratio trajectory across the lifespan. *Seizure* 2019; 75: 63-65.
13. Popkirov S, **Asadi-Pooya AA**, Duncan R, et al. The aetiology of psychogenic non-epileptic seizures: risk factors and comorbidities. *Epileptic Disord* 2019; 21: 529-547.
14. **Asadi-Pooya AA**, Homayoun M. Structural brain abnormalities in patients with psychogenic nonepileptic seizures. *Neurol Sci.* 2019 Nov 12. doi: 10.1007/s10072-019-04108-7. [Epub ahead of print].
15. **Asadi-Pooya AA**, Asadi-Pooya K, AlBaradie RS. Gut microbiota and psychogenic non-epileptic seizures; are they related? *Expert Rev Neurother* 2019; 19: 1163.
16. Ashjzadeh N, Sahraeian A, Sabzgolil I, **Asadi-Pooya AA**. Attention deficit-hyperactivity disorder in adults with epilepsy. *Epilepsy Behav* 2019; 101(Pt A): 106543.
17. **Asadi-Pooya AA**, Homayoun M, Sharifi S. Complementary and integrative medicine in epilepsy: what patients and physicians perceive. *Epilepsy Behav* 2019; 101(Pt A): 106545.
18. **Asadi-Pooya AA**. Pathophysiology of psychogenic nonepileptic attacks. *JAMA* 2019; 322: 1315.
19. **Asadi-Pooya AA**. Semiological classification of psychogenic nonepileptic seizures: a systematic review and a new proposal. *Epilepsy Behav* 2019; 100(Pt A): 106412.
20. Mesraoua B, Deleu D, Al Hail H, Melikyan G, Boon P, Haider HA, **Asadi-Pooya AA**. Electroencephalography in epilepsy; Look for what could be beyond the visual inspection. *Neurol Sci* 2019; 40: 2287-2291.

21. Oroji F, Hoseini SM, **Asadi-Pooya AA**. Quality of electroencephalography recordings in neurology clinics in Iran. *Epileptic Disord* 2019; 21: 375-378.
22. **Asadi-Pooya AA**, Bahrami Z. Frequency of attacks in patients with psychogenic nonepileptic seizures. *Epileptic Disord* 2019; 21: 371-374.
23. Sharifian Dorche M, Sharifian Dorche AH, **Asadi-Pooya AA**. Psychogenic nonepileptic seizures publications in PubMed: Geographical distribution of the publications. *Seizure* 2019; 71: 240-244.
24. **Asadi-Pooya AA**, Valente K, Restrepo AD, et al. Adult-onset psychogenic nonepileptic seizures: A multicenter international study. *Epilepsy Behav* 2019;98(Pt A):36-39.
25. Mesraoua B, Deleu D, Kullmann DM, Shetty AK, Boon P, Perucca E, Mikati MA, **Asadi-Pooya AA**. Novel therapies for epilepsy in the pipeline. *Epilepsy Behav* 2019; 97: 282-290.
26. **Asadi-Pooya AA**, Sperling MR. Normal Awake, Drowsy, and Sleep EEG Patterns That Might Be Overinterpreted as Abnormal. *J Clin Neurophysiol* 2019; 36: 250-256.
27. **Asadi-Pooya AA**, Myers L, Valente K, et al. Sex differences in demographic and clinical characteristics of psychogenic nonepileptic seizures: A retrospective multicenter international study. *Epilepsy Behav* 2019; 97: 154-157.
28. Bahrami Z, Homayoun M, **Asadi-Pooya AA**. Why is psychogenic nonepileptic seizure diagnosis missed? A retrospective study. *Epilepsy Behav* 2019; 97: 135-137.
29. **Asadi-Pooya AA**, Myers L, Valente K, et al. Pediatric-onset psychogenic nonepileptic seizures: A retrospective international multicenter study. *Seizure* 2019; 71: 56-59.
30. **Asadi-Pooya AA**. Re: Establishment of low cost epilepsy surgery centers in resource poor settings. *Seizure* 2019; 71: 28.

31. **Asadi-Pooya AA**, Sahraian MA, Sina F, et al. Management of seizures in patients with multiple sclerosis; an Iranian consensus. *Epilepsy Behav* 2019; 96: 244-248.
32. **Asadi-Pooya AA**, Bahrami Z. Auras in psychogenic nonepileptic seizures. *Seizure* 2019; 69: 215-217.
33. **Asadi-Pooya AA**, Azizimalamiri R, Badv RS, et al. Impacts of the international economic sanctions on Iranian patients with epilepsy. *Epilepsy Behav* 2019; 95: 166-168.
34. **Asadi-Pooya AA**, Bahrami Z. Sexual abuse and psychogenic nonepileptic seizures. *Neurol Sci*. 2019 Apr 14. doi: 10.1007/s10072-019-03887-3. [Epub ahead of print]
35. **Asadi-Pooya AA**, Bahrami Z. Loss of responsiveness in psychogenic non-epileptic seizures. *Epileptic Disord* 2019; 21: 192-196.
36. **Asadi-Pooya AA**, Bahrami Z. Parental consanguinity in patients with psychogenic nonepileptic seizures. *Epilepsy Behav* 2019; 94: 167-168.
37. **Asadi-Pooya AA**, Forouzesh M, Eidi H, Mirzaghafour SE. Levetiracetam versus carbamazepine in treatment of rolandic epilepsy. *Epilepsy Behav* 2019; 94: 1-8.
38. Mohammadi M, Kowkabi S, **Asadi-Pooya AA**, Malamiri RA, Badv RS. Hemi-ESES associated with agenesis of the corpus callosum and normal cognition. *Epilepsy Behav Case Rep* 2019; 11: 96-98.
39. **Asadi-Pooya AA**, Bahrami Z, Homayoun M. Natural history of patients with psychogenic nonepileptic seizures. *Seizure* 2019; 66: 22-25.
40. **Asadi-Pooya AA**, Bahrami Z. Dramatic presentations in psychogenic nonepileptic seizures. *Seizure* 2019; 65: 144-147.
41. **Asadi-Pooya AA**, Bahrami Z. Education in patients with psychogenic nonepileptic seizures. *Seizure* 2019; 64: 74-76.

42. **Asadi-Pooya AA**, AlBaradie R, Sawchuk T, et al. Psychogenic nonepileptic seizures in children and adolescents: an international cross-cultural study. *Epilepsy Behav* 2018; 90: 90-92.
43. **Asadi-Pooya AA**, Bahrami Z. Risk factors for the use of antiepileptic drugs in patients with psychogenic nonepileptic seizures. *Epilepsy Behav* 2018; 90: 119-121.
44. Wilkins SS, Mesraoua B, Palomo GA, Al Hail H, Salam A, Melikyan G, Azar N, Haddad N, Uthman B, Siddiqi M, Elsheikh L, Ali M, Alrabi A, Shuaib A, Deleu D, **Asadi-Pooya AA**. Characteristics of patients with confirmed epilepsy and psychogenic nonepileptic seizures in Qatar. *Epilepsy Behav* 2018; 85: 218-221.
45. Miller J, Watrous AJ, Tsitsiklis M, Lee SA, Sheth SA, Schevon CA, Smith EH, Sperling MR, Sharan A, **Asadi-Pooya AA**, Worrell GA, Meisenhelter S, Inman CS, Davis KA, Lega B, Wanda PA, Das SR, Stein JM, Gorniak R, Jacobs J. Lateralized hippocampal oscillations underlie distinct aspects of human spatial memory and navigation. *Nat Commun* 2018; 9(1): 2423.
46. **Asadi-Pooya AA**. Yield of EEG monitoring in children with developmental disabilities is high. *Epilepsy Behav* 2018; 84: 105-106.
47. **Asadi-Pooya AA**, Ziyae F. Outcome of patients with psychogenic nonepileptic seizures with limited resources: A longitudinal study. *Seizure* 2018; 59: 1-4.
48. **Asadi-Pooya AA**, Kanemoto K, Kwon OY, Taniguchi G, Dong Z, Chinvarun Y, Yu HY, McGonigal A, Kanner AM, Park SP. *Seizure* 2018; 57: 45-49.
49. **Asadi-Pooya AA**. Lennox-Gastaut syndrome: a comprehensive review. *Neurol Sci* 2018; 39(3): 403-414.
50. **Asadi-Pooya AA**, Valente K, Alessi R, Tinker J. Semiology of psychogenic nonepileptic seizures: An international cross-cultural study. *Epilepsy Behav* 2017; 75: 210-212.

51. **Asadi-Pooya AA**, Tinker J. Delay in diagnosis of psychogenic nonepileptic seizures in adults: A post hoc study. *Epilepsy Behav* 2017; 75: 143-145.
52. **Asadi-Pooya AA**, Shabo L, Wyeth D, Nei M. Ictal coughing: clinical features and differential diagnoses. *Epilepsy Behav* 2017; 73:51-53.
53. **Asadi-Pooya AA**. Psychogenic nonepileptic seizures; a concise review. *Neurol Sci* 2017; 38(6):935-940.
54. Weiss SA, **Asadi-Pooya AA**, Moy S, et al. AR2, a novel automatic artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software. *Epilepsy Res* 2017; 6: 30.
55. **Asadi-Pooya AA**, Tinker J, Fletman EW. How variable are psychogenic nonepileptic seizures? A retrospective semiological study. *J Neurol Sci* 2017; 377: 85-87.
56. **Asadi-Pooya AA**, Sperling MR, Chung S, et al. Efficacy and tolerability of brivaracetam in patients with prior antiepileptic drug exposure: a descriptive post hoc study. *Epilepsy Res* 2017; 131: 70-75.
57. **Asadi-Pooya**, Rostami C. History of surgery for temporal lobe epilepsy. *Epilepsy Behav* 2017; 70(Pt A): 57-60.
58. Asadollahi M, Sperling MR, Rabiei AH, **Asadi-Pooya AA**. Drug-resistant parietal lobe epilepsy: clinical manifestations and surgery outcome. *Epileptic Disord* 2017; 19(1): 35-39.
59. **Asadi-Pooya AA**, Stewart GR, Abrams DJ, Sharan A. Prevalence and incidence of drug-resistant mesial temporal lobe epilepsy in the United States. *World Neurosurg* 2017; 99: 662-666.
60. **Asadi-Pooya AA**, Rakei SM, Kamgarpour A, Taghipour M, Ashjzadeh N, Razmkon A, Zare Z, Bagheri MH. Outcome after temporal lobectomy in patients with medically-refractory mesial temporal epilepsy in Iran. *J Neurosurg Sci* 2017; 61(3): 277-282.

61. **Asadi-Pooya AA**, Fletman EW. Ictal kissing: occurrence and etiology. *Neurol Sci* 2017; 38(2): 353-355.
62. **Asadi-Pooya AA**, Nei M, Centurion EE, Lorenzo M, Sperling MR. Postsurgical outcome in patients with olfactory auras and drug-resistant epilepsy. *Epilepsy Behav* 2017; 68: 8-10.
63. **Asadi-Pooya AA**. Electroconvulsive therapy and epilepsy. *Epilepsia* 2017; 58(1): 176-177.
64. Carreño M, Bien CG, **Asadi-Pooya AA**, et al. Epilepsy surgery in drug-resistant temporal lobe epilepsy associated with antineuronal antibodies. *Epilepsy Res* 2017; 129: 101-105.
65. **Asadi-Pooya AA**, Nei M, Rostami C, Sperling MR. Mesial temporal lobe epilepsy with childhood febrile seizure. *Acta Neurol Scand* 2017; 135(1): 88-91.
66. **Asadi-Pooya AA**, Nei M, Sharan A, Sperling MR. Postsurgical outcome in patients with auditory auras and drug-resistant epilepsy. *Epilepsy Behav* 2016; 66: 49-52.
67. **Asadi-Pooya AA**, Razavizadegan MA, Sahraian A, Sahmeddini MA. Adjunctive use of electroconvulsive therapy in patients with Lennox-Gastaut syndrome and drug-resistant epilepsy: A pilot study. *Med J Islam Repub Iran* 2016; 30: 413.
68. **Asadi-Pooya**. “Seizure disorder” is a suboptimal terminology! *Epilepsy Behav* 2016; 64(Pt A): 289.
69. **Asadi-Pooya AA**, Rabiei AH, Tinker J, Tracy J. Review of systems questionnaire helps differentiate psychogenic nonepileptic seizures from epilepsy. *J Clin Neurosci* 2016; 34: 105-107.
70. Kinney MO, Sperling MR, Barshow S, Nei M, **Asadi-Pooya AA**. A reappraisal of mortality after epilepsy surgery. *Neurology* 2016; 87(19): 2067.
71. **Asadi-Pooya AA**. Zika virus-associated seizures. *Seizure* 2016; 43: 13.

72. **Asadi-Pooya AA**, Asadollahi M, Tinker J, Nei M, Sperling MR. Post-epilepsy surgery psychogenic nonepileptic seizures. *Epilepsia* 2016; 57(10):1691-1696.
73. Gutierrez C, Tobochnik SD, **Asadi-Pooya AA**, Skidmore CT, LoPinto-Khoury C, Sperling MR. Clinical features and postoperative seizure outcome in patients with drug-resistant gelastic seizures without hypothalamic hamartoma. *Epilepsy Behav* 2016; 64(Pt A): 90-93.
74. **Asadi-Pooya, AA**, Tinker J, Fletman E. Semiological classification of psychogenic nonepileptic seizures. *Epilepsy Behav* 2016; 64(Pt A):1-3.
75. **Asadi-Pooya AA**, Asadollahi M, Bujarski K, Rabiei AH, Aminian N, Wyeth D, et al. Ictal verbal help-seeking: Occurrence and the underlying etiology. *Epilepsy Behav* 2016; 64(Pt A): 15-17.
76. **Asadi-Pooya AA**, Nei M, Sharan A, Sperling MR. Seizure clusters in drug-resistant focal epilepsy. *Epilepsia* 2016; 57(9): e187-190.
77. **Asadi-Pooya AA**, Rabiei AH, Gracely EJ, Sperling MR. Remote preoperative tonic-clonic seizures do not influence outcome after surgery for temporal lobe epilepsy. *J Neurol Sci* 2016; 369: 330-332.
78. Moseley BD, Sperling MR, **Asadi-Pooya AA**, et al. Efficacy, safety and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three Phase III studies. *Epilepsy Res* 2016; 127: 179-185.
79. **Asadi-Pooya AA**, Xiao F, Zhou D. Real-time effects of centrotemporal spikes on cognition in rolandic epilepsy: An EEG-fMRI study. *Neurology* 2016; 87(5): 551-552.
80. **Asadi-Pooya**. Phenytoin for neuroprotection. *Lancet Neurol* 2016; 15(9): 901.
81. **Asadi-Pooya AA**. Biological underpinnings of psychogenic nonepileptic seizures: directions for future research. *Neurol Sci* 2016; 37(7): 1033-1038.

82. **Asadi-Pooya AA**. Determinants of epilepsy surgery failure: Etiology matters. *Brain* 2016; 139(Pt 7): e37.
83. **Asadi-Pooya AA**, et al. Patient historical risk factors associated with seizure outcome after surgery for drug-resistant nonlesional temporal lobe epilepsy. *World Neurosurg* 2016; 91: 205-209.
84. **Asadi-Pooya AA**, et al. Historical risk factors associated with seizure outcome after surgery for drug-resistant mesial temporal lobe epilepsy. *World Neurosurg* 2016; 89: 78-83.
85. **Asadi-Pooya AA**, Asadollahi M, Shimamoto S, Lorenzo M, Sperling MR. Spike voltage topography in temporal lobe epilepsy. *J Neurol Sci* 2016; 366: 209-212.
86. **Asadi-Pooya AA**. Psychogenic nonepileptic seizures are predominantly seen in women: potential neurobiological reasons. *Neurol Sci* 2016. 37(6): 851-855.
87. **Asadi-Pooya AA**, M Asadollahi, Sperling MR. Ictal pain: occurrence, clinical features, and underlying etiologies. *Epilepsy Behav* 2016; 61: 59-62.
88. **Asadi-Pooya**. Psychogenic nonepileptic seizures and sex differences in stress responses. *Epilepsia* 2016; 57(5): 853.
89. Sperling MR, Barshow S, Nei M, **Asadi-Pooya AA**. A reappraisal of mortality after epilepsy surgery. *Neurology* 2016; 86(21): 1938-1944.
90. **Asadi-Pooya, AA**, Wyeth D, Sperling MR. Ictal crying. *Epilepsy Behav* 2016; 59:1-3.
91. **Asadi-Pooya AA**, Nei M, Sharan A, Sperling MR. Auras in patients with temporal lobe epilepsy and mesial temporal sclerosis. *J Neurol Sci* 2016; 364:24-6.
92. **Asadi-Pooya AA**. Availability of antiepileptic drugs: Politicians' roles. *Epilepsia* 2016; 57(4):671.
93. **Asadi-Pooya AA**. Psychogenic non-epileptic seizures in adult neurology clinics in southern Iran: A survey of neurologists. *Iran J Neurol* 2016; 15(2): 100-102.

94. **Asadi-Pooya**. An fMRI study to identify the neurobiological link between sex abuse and psychogenic nonepileptic seizures. *Epilepsy Behav* 2016; 57(Pt A): 222.
95. **Asadi-Pooya AA**. Reproductive disorders in patients with epilepsy; we need high quality studies. *Epilepsia* 2016; 57(1): 16516-6.
96. **Asadi-Pooya AA**, Farazdaghi M. Seizure outcome in patients with juvenile absence epilepsy. *Neurol Sci* 2016; 37(2): 289-292.
97. **Asadi-Pooya AA**, Nei M, Sperling MR. Seasonality of birth in patients with temporal lobe epilepsy. *Acta Neurol Scand* 2016; 134(1): 87-9.
98. **Asadi-Pooya AA**, Tavana B, Tavana B, Emami M. Drug adherence of patients with epilepsy in Iran: the effects of the international economic sanctions. *Acta Neurol Belg* 2016; 116(2): 151-155.
99. **Asadi-Pooya AA**, Rostami C, Rabiei AH, Sperling MR. Factors associated with tonic-clonic seizures in patients with drug-resistant mesial temporal epilepsy. *J Neurol Sci* 2015; 359 (1-2): 452-454.
100. **Asadi-Pooya AA**, Tajvarpour M, Vedadinezhad B, Emami M. Comparison of temporal lobe epilepsy with hippocampal sclerosis and temporal lobe epilepsies due to other etiologies. *Med J Islam Repub Iran* 2015; 29: 263.
101. **Asadi-Pooya AA**. Are psychogenic nonepileptic seizures genetically determined? It is time to explore! *Seizure* 2015; 32: 43-44.
102. **Asadi-Pooya AA**. Neurobiological origin of psychogenic nonepileptic seizures: A review of imaging studies. *Epilepsy Behav* 2015; 52(Pt A): 256-259.
103. **Asadi-Pooya AA**, Sperling MR. Age at onset in patients with medically-refractory temporal lobe epilepsy and mesial temporal sclerosis: impact on clinical manifestations and postsurgical outcome. *Seizure* 2015; 30: 42-45.

104. **Asadi-Pooya AA**, Nei M, Sharan A, Sperling MR. Type of preoperative aura may predict postsurgical outcome in patients with temporal lobe epilepsy and mesial temporal sclerosis. *Epilepsy Behav* 2015; 50: 98-100.
105. **Asadi-Pooya AA**, Farazdaghi M, Ashjazadeh N. Effects of carbamazepine on semen parameters in men with newly diagnosed epilepsy. *Iran J Neurol* 2015; 14(3): 168-170.
106. **Asadi-Pooya AA**. High dose folic acid supplementation in women with epilepsy: are we sure it is safe? *Seizure* 2015; 27: 51-53.
107. **Asadi-Pooya AA**, Sperling MR. Epidemiology of psychogenic non-epileptic seizures. *Epilepsy Behav* 2015; 46:60-65.
108. **Asadi-Pooya AA**, Hashemzahi Z, Emami M. Epidemiology and clinical manifestations of juvenile myoclonic epilepsy (JME) in Iran. *Neurol Sci* 2015; 36(5): 713-716.
109. **Asadi-Pooya AA**. Commissural reconnection; a possible reason for failure of corpus callosotomy in refractory epilepsy. *Epilepsy Behav* 2015; 42: 2.
110. **Asadi-Pooya AA**, Jalali Jahromi M, Izadi S, Emami Y. Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings. *Seizure* 2015; 24: 114-117.
111. **Asadi-Pooya AA**, Dabbaghmanesh MH, Ashjazadeh N. Effects of carbamazepine on male reproductive hormones. *Med J Islam Repub Iran* 2014; 28: 139.
112. **Asadi-Pooya AA**, Hashemzahi Z, Emami M. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME). *Seizure* 2014; 23(10): 889-891.

113. Ashjazadeh N, Kashani K, Sahraian A, **Asadi-Pooya AA**. Frequency of depression and anxiety among patients with psychogenic non-epileptic seizures. *GMJ* 2014; 3(4): 202-206
114. Seifi A, **Asadi-Pooya AA**, et al. The epidemiology, risk factors, and impact on hospital mortality of status epilepticus after subdural hematoma in the United States. *Springerplus* 2014 Jul 1; 3: 332.
115. **Asadi-Pooya AA**, Ashjazadeh N, Kamgarpour A, Rakei SM, Taghipour M, Farazdaghi M, Inaloo S, Bagheri MH, Razmkon A, Zare Z. Management of epilepsy in resource-limited settings: establishing an epilepsy surgery program in Iran. *Med J Islam Repub Iran* 2014; 28: 24.
116. **Asadi-Pooya AA**, Emami M, Emami Y. Ictal injury in psychogenic non-epileptic seizures. *Seizure* 2014; 23(5):363-366.
117. **Asadi-Pooya AA**. Transient epileptic amnesia: A concise review. *Epilepsy Behav* 2014; 31: 243-245.
118. **Asadi-Pooya AA**, Emami M. Perception and use of complementary and alternative medicine among children and adults with epilepsy: The importance of the decision makers. *Acta Med Iran* 2014; 52(2): 153-157.
119. **Asadi-Pooya AA**, Emami Y, Emami M. Psychogenic non-epileptic seizures in Iran. *Seizure* 2014; 23(3): 175-177.
120. **Asadi-Pooya AA**, Emami Y, Emami M, Sperling MR. Prolonged psychogenic non-epileptic seizures or pseudostatus. *Epilepsy Behav* 2014; 31: 304-306.
121. Amoozgar H, Saleh F, Farhani N, Rafiei M, Inaloo S, **Asadi-Pooya AA**. Cardiac repolarization changes in the children with breath-holding spells. *Iran J Pediatr* 2013; 23(6): 687-692.

122. **Asadi-Pooya AA**, Malekmohamadi Z, Kamgarpour A, Rakei SM, Taghipour M, Ashjazadeh N, Inaloo S, Razmkon A, Zare Z. Corpus callosotomy is a valuable therapeutic option for patients with Lennox-Gastaut syndrome and medically-refractory seizures. *Epilepsy Behav* 2013; 29(2): 285-288.
123. **Asadi-Pooya AA**, Shokouhyar S, Emami M, Sharifzade M. Perception and use of complementary and alternative medicine among patients with epilepsy. *Arch Neurosci* 2013; 1(2): 60-66.
124. **Asadi-Pooya AA**, Emami M. Juvenile and adult-onset psychogenic non-epileptic seizures. *Clin Neurol Neurosurg* 2013; 115(9): 1697-1700.
125. **Asadi-Pooya AA**, Razavizadegan SMA, Abdi-Ardekani A, Sperling MR. Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy. *Epilepsy Behav* 2013; 29(1): 150-154.
126. **Asadi-Pooya AA**, Sharifzade M. West syndrome in south Iran: electro-clinical manifestations. *Iran J Child Neurol* 2013; 7(3): 40-44.
127. **Asadi-Pooya AA**, Emami M, Emami Y. Gender differences in manifestations of psychogenic non-epileptic seizures in Iran. *J Neurol Sci* 2013; 332(1-2): 66-68.
128. **Asadi-Pooya AA**, Emami M. Demographic and clinical manifestations of psychogenic non-epileptic seizures: The impact of co-existing epilepsy in patients or their family members. *Epilepsy Behav* 2013; 27(1): 1-3.
129. **Asadi-Pooya AA**, Emami M, Ashjazadeh N, Nikseresht A, Shariat A, Petramfar P, Yousefipour G, Borhani-Haghighi A, Izadi S, Rahimi-Jaberi A. Reasons for uncontrolled seizures in adults; the impact of pseudointractability. *Seizure* 2013; 22(4): 271-274.
130. **Asadi-Pooya AA**, Emami M, Sperling MR. A clinical study of syndromes of idiopathic (genetic) generalized epilepsy. *J Neurol Sci* 2013; 324(1-2): 113-117.

131. **Asadi-Pooya AA**, Sharifzade M. Lennox-Gastaut syndrome in south Iran: electro-clinical manifestations. *Seizure* 2012; 21(10): 760-763.
132. **Asadi-Pooya AA**, Emami M. Reasons for uncontrolled seizures in children; the impact of pseudointractability. *Epilepsy Behav* 2012; 25(3): 341-344.
133. **Asadi-Pooya AA**, Emami M, Sperling MR. Age of onset in idiopathic (genetic) generalized epilepsies: clinical and EEG findings in various age groups. *Seizure* 2012; 12: 417-421.
134. **Asadi-Pooya AA**, Emami M. Is interictal EEG correlated with the seizure type in idiopathic (genetic) generalized epilepsies? *Iran J Child Neurol* 2012; 6(2): 25-28.
135. **Asadi-Pooya AA**, Emami M, Nikseresht AR. Early-onset versus typical childhood absence epilepsy; clinical and electrographic characteristics. *Seizure* 2012; 21: 273-275.
136. **Asadi-Pooya AA**, Torabi-Nami M. Knowledge and attitude towards epilepsy among biology teachers in Fars Province, Iran. *Iran J Child Neurol* 2012; 6(1): 13-18.
137. **Asadi-Pooya AA**, Nikseresht AR, Yaghoobi E. Old remedies for epilepsy: Avicenna's medicine. *IRCMJ* 2012; 14(3): 174-177.
138. **Asadi-Pooya AA**, Nikseresht AR, Yaghoobi E, Nei M. Physical injuries in patients with epilepsy and their associated risk factors. *Seizure* 2012; 21: 165-168.
139. **Asadi-Pooya AA**, Dehghani SM, Petramfar P, Emami M, Mahmoodi M. Helicobacter pylori infection in patients with epilepsy. *Seizure* 2012; 21(1): 21-23.
140. **Asadi-Pooya AA**, Dehghani SM, Petramfar P, Emami M. Effect of treating helicobacter pylori infection on seizure frequency in patients with refractory epilepsy. *Iran J Neurol* 2011; 10(3-4): 51-53.

141. **Asadi-Pooya AA**, Emami M. Effects of antiepileptic drugs on electroencephalographic findings in patients with idiopathic generalized epilepsies. Iran J Child Neurol 2011; 5(4): 33-36.
142. **Asadi-Pooya AA**, Sperling MR. Depression and anxiety in patients with epilepsy with or without other chronic disorders. IRCMJ 2011; 13(2): 112-116.
143. **Asadi-Pooya AA**, Yaghoobi E, Nikseresht AR, Moghadami M, Honarvar B. The neurological manifestations of H1N1 influenza infection; diagnostic challenges and recommendations. Iran J Med Sci 2011; 36(1): 36-39.
144. **Asadi-Pooya AA**, Nikseresht AR, Yaghoobi E. Vasovagal syncope treated as epilepsy for 16 years. Iran J Med Sci 2011; 36(1): 60-62.
145. **Asadi-Pooya AA**, Petramfar P, Taghipour M. Refractory hiccups due to phenytoin therapy. Neurol India 2011; 59(1): 68.
146. Zangaladze A, **Asadi-Pooya AA**, Ashkenazi A, Sperling MR. Sporadic hemiplegic migraine and epilepsy associated with CACNA1A gene mutation. Epilepsy Behav 2010; 17(2): 293-295.
147. **Asadi-Pooya AA**, Sperling MR. Clinical features of sudden unexpected death in epilepsy. J Clin Neurophysiol 2009; 26(5): 297-301.
148. Petramfar P, Yaghoobi E, Nemati R, **Asadi-Pooya AA**. Serum creatine phosphokinase is helpful in distinguishing generalized tonic-clonic seizures from psychogenic non-epileptic seizures and vasovagal syncope. Epilepsy Behav 2009; 15(3):330-332.
149. **Asadi-Pooya AA**, Mintzer S, Sperling, MR. Nutritional supplements, foods, and epilepsy: Is there a relationship? Epilepsia 2008; 49(11):1819-1827.

150. **Asadi-Pooya AA**, Nei M, Sharan AD, Mintzer S, Zangaladze A, Evans JG, Skidmore C, Sperling MR. Antiepileptic drugs and relapse after epilepsy surgery. *Epileptic Disord* 2008; 10(3): 193-198.
151. **Asadi-Pooya AA**, Asadi-Pooya K. Antinuclear antibody in children with epilepsy treated by carbamazepine. *Epilepsy Res* 2008; 80: 229-230.
152. **Asadi-Pooya AA**, Sharan A, Nei M, Sperling MR. Corpus callosotomy. *Epilepsy Behav* 2008; 13: 271-278.
153. **Asadi-Pooya AA**, Sperling MR. Strategies for surgical treatment of epilepsies in developing countries. *Epilepsia* 2008; 49(3): 381-385.
154. Sperling MR, Schilling CA, Glosser D, Tracy JI, **Asadi-Pooya AA**. Self-perception of seizure precipitants and their relation to anxiety level, depression, and health locus of control in epilepsy. *Seizure* 2008; 17(4): 302-307.
155. **Asadi-Pooya AA**, Asadi-Pooya A, Rosen D. Hearing impairment after bacterial and aseptic meningitis in children. *J Ped Neurol* 2008; 6(1): 31-34.
156. Sperling MR, Nei M, Zangaladze A, Sharan AD, Mintzer S, Skidmore C, Evans JG, Schilling CA, **Asadi-Pooya AA**. Prognosis after late relapse following epilepsy surgery. *Epilepsy Res* 2008; 78(1): 77-81.
157. Dehghani SM, **Asadi-Pooya AA**. Celiac disease in children with short stature. *Indian J Pediatr* 2008; 75(2): 131-133.
158. **Asadi-Pooya AA**, Sperling MR. Do foods precipitate seizures? A cross-cultural comparison. *Epilepsy Behav* 2007; 11(3): 450-453.
159. **Asadi-Pooya AA**, Schilling CA, Glosser D, Tracy JI, Sperling MR. Health locus of control in patients with epilepsy and its relation to anxiety and depression. *Epilepsy Behav* 2007; 11(3): 347-350.

160. **Asadi-Pooya AA**, Sperling MR. Potentiation of antiepileptic drugs effectiveness by pyronaridine in refractory epilepsy. *Med Hypotheses* 2007; 69(3): 560-563.
161. **Asadi-Pooya AA**, Bordbar MR. Are laboratory tests necessary in making the diagnosis of growing pains in children? *Pediatr Int* 2007; 49(6): 833-835.
162. **Asadi-Pooya AA**, Ghetmiri E. Allergy and idiopathic generalized epilepsy: A case-control study. *J Ped Neurol* 2007; 5(3): 231-232.
163. **Asadi-Pooya AA**, Ghetmiri E. Red blood cell indices in children with idiopathic epilepsy: a case-control study. *Clin Neurol Neurosurg* 2006; 108(6): 614-615.
164. **Asadi-Pooya AA**, Borzooi M, Amoozgar H. Experiences with 113 patients of Kawasaki disease in Fars province, Iran. *Turk J Pediatr* 2006; 48(2): 109-114.
165. **Asadi-Pooya AA**, Ghetmiri E. Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. *Epilepsy Behav* 2006; 8: 228-231.
166. **Asadi-Pooya AA**, Kashef S. Accuracy of axillary temperature compared with rectal temperature in ill children. *Kuwait Med J* 2006; 38(1): 25-27.
167. **Asadi-Pooya AA**. Risk factors for carbamazepine induced leucopenia in children and adolescents. *J Ped Neurol* 2005; 3(4): 233-235.
168. **Asadi-Pooya AA**, Ghaffari A, Sadeghi E. The necessity of audiometric screening after mumps meningoencephalitis. *Iran J Infect Dis Trop Med* 2005; 10(31): 57-61 (in Persian).
169. **Asadi-Pooya AA**. Epilepsy and consanguinity in Shiraz, Iran. *Eur J Paed Neurol* 2005; 9: 383-386.

170. **Asadi-Pooya AA**, et al. Radiographic findings of childhood lymphoblastic leukemia before and after chemotherapy. *Ahwaz Sci Med J* 2005; 4(2): 123-127 (In Persian).
171. **Asadi-Pooya AA**, Poordast A. Etiologies and outcomes of status epilepticus in children. *Epilepsy Behav* 2005; 7: 502-505.
172. **Asadi-Pooya AA**, Eslami NS, Haghghat M.. Wilson disease in Southern Iran. *Turk J Gastroenterol* 2005; 16(2): 71-74.
173. **Asadi-Pooya AA**. Drug compliance of children and adolescents with epilepsy. *Seizure* 2005; 14(6): 393-395.
174. **Asadi-Pooya AA**, Hossein-Zade A. What do nurses and physicians think about the need for specific dietary restrictions in the patients with epilepsy? *Epilepsy Behav* 2005; 6(4): 604-606.
175. **Asadi-Pooya AA**, et al. Mumps meningoencephalitis: clinical manifestations and cerebro-spinal fluid findings. *Iran J Infect Dis Trop Med* 2005; 9(27): 69-71 (in Persian).
176. **Asadi-Pooya AA**, Hojabri K. Risk factors for childhood epilepsy: a case-control study from Shiraz, Iran. *Epilepsy Behav* 2005; 6(2): 203-206.
177. **Asadi-Pooya AA**, Ghaffari A. Do patients with epilepsy believe they need specific dietary restrictions? *Epilepsy Behav* 2004; 5(6): 945-948.
178. **Asadi-Pooya AA**, Karamifar H. Body mass index in children with beta-thalassemia major. *Turk J hematol* 2004; 21(4): 177-180.
179. **Asadi-Pooya AA**, Karimi M, Imanieh MH. Growth retardation in children with thalassemia major. *Haema* 2004; 7(4): 493-496.
180. **Asadi-Pooya AA**, Doroudchi M. Thalassemia major and consanguinity in Shiraz city Iran. *Turk J Hematol* 2004; 21(3): 127-130.

181. **Asadi-Pooya AA**, Panjehshahin MR, Beheshti S. The antimycobacterial effect of honey. Riv Biol/ B. Forum 2003; 96(3): 491-496.
182. **Asadi-Pooya AA**, et al. Disturbances in calcium metabolism in childhood lymphoblastic leukemia, before and after chemotherapy. Iran J Endocrinol Metabol 2003; 5(3): 211-214 (in Persian).
183. Karimi M, **Asadi-Pooya AA**, et al. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients. Acta Hematol 2002; 108(2): 79-83.
184. **Asadi-Pooya AA**, Sadeghi-Hasanabadi A. Circadian rhythm of normal vaginal deliveries. Reprod Infertil 2001; 2(7): 54-58 (in Persian).
185. **Asadi-Pooya AA**, Shahriari M. Prophylactic antibiotic in splenectomized thalassemic children. Teb-0-Tazkie 1999; 10: 49-54 (in Persian).

B. Books:

1. **Asadi-Pooya AA**, Dlugos D, Skidmore C, Sperling MR. Atlas of Electroencephalography Patterns. **Third Edition, 2017**, Epileptic Disord 2017 Sep 1; 19(3): 384. doi: 10.1684/epd.2017. 0934.
2. **Asadi-Pooya AA** & Sperling MR. Antiepileptic Drugs: A Clinician's Manual. **Second Edition**. New York, Oxford University Press; 2016.
3. **Asadi-Pooya AA**, Dlugos D, Skidmore C, Sperling MR. Atlas of Electroencephalography Patterns. **Second Edition, 2015**, Thomas Jefferson University, Web-based Digital EEG Atlas. Published on "Epileptic Disorders" 2015 (http://www.jle.com/en/revues/epd/e-docs/atlas_of_electroencephalography_305272/article.phtml).

4. **Asadi-Pooya AA** & Shokouhyar S. Idiopathic (genetic) generalized epilepsies. Shiraz, Iran; Shiraz University of Medical Sciences Publications; 2014.
5. **Asadi-Pooya AA**. Imaging in Epilepsy. Shiraz, Iran; Shiraz University of Medical Sciences Publications; 2014.
6. **Asadi-Pooya AA**. Atlas of Ictal EEG. Shiraz, Iran; Shiraz University of Medical Sciences Publications; 2014.
7. **Asadi-Pooya AA** & Sperling MR. Atlas of EEG reports. Shiraz, Iran; Shiraz University of Medical Sciences Publications; 2014.
8. **Asadi-Pooya AA** & Ashjazadeh N. Epilepsy Information for All. Shiraz, Iran; Neurosciences Research Center Publications, Shiraz University of Medical Sciences; 2011.
9. Nikseresht AR & **Asadi-Pooya AA**. Status Epilepticus. Shiraz, Iran; Shiraz Comprehensive Epilepsy Center Publications; 2011.
10. **Asadi-Pooya AA** & Sperling MR. Antiepileptic Drugs: A Clinician's Manual. Oxford University Press, 2009.
11. **Asadi-Pooya AA**, Dlugos D, Skidmore C, Sperling MR. Atlas of Electroencephalography Patterns. Philadelphia; Thomas Jefferson University, Web-based Digital EEG Atlas; 2008.

Book Chapters

1. Epilepsy and Cerebral Palsy. Boulenouar Mesraoua, Musab Ali, Dirk Deleu, Hassan Al Hail, Gayane Melikyan, Naim Haddad, Osama Alalamy, Covanis Athanasios and **Ali A. Asadi-Pooya**. © 2019 The Author(s). Licensee IntechOpen.

2. Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad General Hospital, Doha, Qatar. Boulenouar Mesraoua, Dirk Deleu, Hassan Al Hail, Musab Ali, Naim Haddad, Gayane Melykian, Yasser Osman M. Ali, Lubna El Sheikh, **Ali A. Asadi-Pooya** and Peter Kaplan. © 2019 The Author(s). Licensee IntechOpen.
3. **Asadi-Pooya AA.** Psychogenic Nonepileptic Seizures, In: Hospital Physician Board Review Manual: EPILEPSY Board Review Manual; Volume 3, Part 3, November 16, 2015; Turner White Communications, Wayne, PA.

Conference Presentations

1. **Asadi-Pooya AA.** Adult-onset psychogenic nonepileptic seizures: A multicenter international study. The 73rd Annual Meeting of the American Epilepsy Society, Baltimore, USA, 2019.
2. **Asadi-Pooya AA.** Auras in psychogenic nonepileptic seizures. XXIV World Congress of Neurology, Dubai, UAE, 2019.
3. **Asadi-Pooya AA.** Sex differences in demographic and clinical characteristics of psychogenic nonepileptic seizures: a retrospective multicenter international study. XXIV World Congress of Neurology, Dubai, UAE, 2019.
4. **Asadi-Pooya AA.** Outcome of patients with psychogenic nonepileptic seizures with limited resources: A longitudinal study. The 13th European Congress on Epileptology, Vienna, Austria, 2018.
5. **Asadi-Pooya AA.** Semiology of psychogenic nonepileptic seizures: An international cross-cultural study. The 13th European Congress on Epileptology, Vienna, Austria, 2018.

6. **Asadi-Pooya AA.** Psychogenic Non-Epileptic Seizures Are Important! The 71st Annual Meeting of the American Epilepsy Society, Washington DC, USA, 2017.
7. **Asadi-Pooya AA.** Management of Epilepsy in Resource-Limited Settings: Establishing an Epilepsy Surgery Program. The 32nd International Epilepsy Congress, Barcelona, Spain, 2017.
8. **Asadi-Pooya AA,** Tinker J, Nei M, Asadollahi M, Sperling MR. Psychogenic nonepileptic seizures after surgery for drug-resistant epilepsy. The 70th Annual Meeting of the American Epilepsy Society, Houston, USA, 2016.
9. **Asadi-Pooya AA,** Emami M. How to succeed in dealing with uncontrolled seizures. The 31st International Epilepsy Congress, Istanbul, Turkey, 2015.
10. **Asadi-Pooya AA,** Sperling MR. Age at onset in patients with medically-refractory temporal lobe epilepsy and mesial temporal sclerosis. The 69th Annual Meeting of the American Epilepsy Society, Philadelphia, USA, 2015.
11. **Asadi-Pooya AA,** et al. Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy. The 67th Annual Meeting of the American Epilepsy Society, Washington DC, USA, 2013.
12. **Asadi-Pooya AA.** Lateralizing and localizing findings in focal epilepsies. The 10th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2013.
13. **Asadi-Pooya AA,** et al. Clinical and EEG findings in idiopathic (genetic) generalized epilepsies: are there any distinctive features to distinguish syndromes? The 66th Annual Meeting of the American Epilepsy Society, San Diego, USA, 2012.
14. **Asadi-Pooya AA.** Common Mistakes in Reading EEG. The 9th International Epilepsy Congress, Tehran, Iran, 2012.

15. **Asadi-Pooya AA**, et al. Interictal EEG does not correlate with the seizure type in idiopathic generalized epilepsies. The 65th Annual Meeting of the American Epilepsy Society, Baltimore, USA, 2011.
16. **Asadi-Pooya AA**. Devices in the management of epilepsy. The 8th International Epilepsy Congress, Tehran, Iran, 2011.
17. **Asadi-Pooya AA**. Food and epilepsy. The 7th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2010.
18. **Asadi-Pooya AA**, et al. Preliminary Results of Epilepsy Surgery in Shiraz, Iran. The First International Epilepsy Congress, Mashhad, Iran, 2010.
19. **Asadi-Pooya AA**. Epilepsy Surgery in Developing Countries. The 5th Iranian Epilepsy Association Annual Congress, Tehran, Iran, 2008.
20. **Asadi-Pooya AA**. Epilepsy Surgery in Children. The 8th Iranian Congress on Pediatric Neurology, Mashhad, Iran, 2008.
21. **Asadi-Pooya AA**, et al. Antiepileptic Drugs and Relapse after Epilepsy Surgery. The 60th American Academy of Neurology Annual Meeting, Chicago, USA, 2008.
22. **Asadi-Pooya AA**, Sperling MR. Depression and Anxiety in Epilepsy Patients with or without other Chronic Disorders. The 61th American Epilepsy Society Annual Meeting, Philadelphia, USA, 2007.
23. Zangaladze A, **Asadi-Pooya AA**, et al. Familial Hemiplegic Migraine Type 1, Cerebellar Ataxia and Epilepsy, Associated with CACNA1A Gene Mutation: a case report. The 61th American Epilepsy Society Annual Meeting, Philadelphia, USA, 2007.
24. **Asadi-Pooya AA**, et al. Health Locus of Control in Patients with Epilepsy and its Relation to Anxiety and Depression. The 59th American Academy of Neurology Annual Meeting, Boston, USA, 2007.

25. Sperling MR, **Asadi-Pooya AA**, et al. Self-perception of Seizure Precipitants and Their Relation to Anxiety Level, Depression, and Health Locus of Control in Epilepsy. The 59th American Academy of Neurology Annual Meeting, Boston, USA, 2007.
26. **Asadi-Pooya AA**, Ghetmiri E. Folic Acid Supplementation Can Prevent Some Blood Cell Abnormalities in Children Receiving Carbamazepine. The 26th International Epilepsy Congress, Paris, France, 2005; **winner of the young investigator award.**
27. **Asadi-Pooya AA**. Risk Factors for Carbamazepine Induced Leucopenia in Children and Adolescents. The 40th Canadian Congress of Neurological Sciences, Ottawa, Canada, 2005.
28. **Asadi-Pooya AA**, Hossein-Zade A. What Do Nurses and Physicians Think about the Need for Specific Dietary Restrictions in the Patients with Epilepsy? The 40th Canadian Congress of Neurological Sciences, Ottawa, Canada, 2005.
29. **Asadi-Pooya AA**. Drug Compliance of Children and Adolescents with Epilepsy. The 4th Iranian Congress of Pediatric Neurology. Bandar-Abbas, Iran, 2005.
30. **Asadi-Pooya AA**, Ghaffari A. Do Patients with Epilepsy Believe They Need Specific Dietary Restrictions? The 11th Asian & Oceanic Congress of Neurology, Singapore, 2004.
31. **Asadi-Pooya AA**, Hojabri K. Risk Factors for Childhood Epilepsy: a case-control study. The 11th Asian & Oceanic Congress of Neurology, Singapore, 2004.
32. **Asadi-Pooya AA**. Landau-Kleffner Syndrome: case presentation. The 3rd Iranian Congress on Pediatric Neurology, Tehran, Iran, 2004.